ORPHA:231183
Usher syndrome type 3
Also known as: USH3
Publications
914
85.8th percentile
Trials
2
Interventional, condition-specific
Researchers
1,147
Distinct authors in sample
Gene link
CLRN1, HARS1
Definitive
Readiness
5/6
Stages with a signal
Clinical definition (Orphanet)
A rare ciliopathy characterized by hearing and visual loss in the first decades of life and, in some cases, vestibular dysfunction. Patients have normal hearing at birth. Onset of hearing loss is usually in late childhood or adolescence after development of speech. Profound deafness is mostly reported by middle age. Retinitis pigmentosa related visual loss also develops in late childhood or adolescence. Developmental motor milestones are generally normal but vestibular dysfunction may occur in adulthood.
How rare: 1-9 / 1 000 000 — roughly one to nine people per million. In a city the size of Kolkata, perhaps a few dozen.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0016485
- UMLS:C1568248
- NCIT:C126329
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
5/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedPresent
Definitive — CLRN1, HARS1
- LiteraturePresent
914 matched papers (701 in last 10 years) Source
- Phenotype characterisedPresent
28 HPO annotations (e.g. Photophobia; Delayed gross motor development; Attenuation of retinal blood vessels) Source
- Animal modelPresent
5 genotype models (Mus musculus) Source
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
2 matched on ClinicalTrials.gov (1 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (CLRN1, HARS1).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
28
Associated phenotypes · MONDO:0016485
- Photophobia
- Delayed gross motor development
- Attenuation of retinal blood vessels
- Bull's eye maculopathy
- Truncal ataxia
Showing 5 of 28 — open Monarch for the full list.
Animal models (Monarch / Alliance)
5
Model associations linked to this Mondo ID
- Clrn1tm1.1Kuna/Clrn1tm1.1Kuna Tg(Atoh1-Clrn1)#Kuna/0 [background:] involves: C57BL/6J·MGI:6156835·Mus musculus
- Clrn1tm2.1Kuna/Clrn1tm2.1Kuna [background:] involves: 129 * BALB/cJ * C57BL/6J·MGI:5432139·Mus musculus
- Clrn1tm2.1Kuna/Clrn1tm2.1Kuna Tg(Atoh1-Clrn1)#Kuna/0 [background:] involves: 129 * C57BL/6J·MGI:6199482·Mus musculus
- Clrn1tm1.1Kuna/Clrn1tm1.1Kuna [background:] involves: C57BL/6J·MGI:3850181·Mus musculus
- Clrn1tm1.1Ugpa/Clrn1tm1.1Ugpa Myo15atm1.1(cre)Ugds/Myo15a+ [background:] involves: 129S1/SvImJ * C57BL/6N·MGI:6467338·Mus musculus
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
914
914 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
914 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
701 in the last 10 years · medium confidence · 85.8th percentile (publications denominator)
Phrase hits: 180 · MeSH hits: 0
Who's working on it?
1,147
Distinct author names in 180 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Sankila EM13 papers · 2013Papers in Europe PMC
- 02Alagramam KN10 papers · 2026
Otolaryngology Head and Neck Surgery, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.
Papers in Europe PMC - 03Millán JM8 papers · 2021
Grupo de Investigación en Enfermedades Neurosensoriales. Instituto de Investigación Sanitaria IIS-La Fe, Semisótano Escuela de Enfermería, Hospital Universitario La Fe, Avda. Campanar, 21, 46009, Valencia, Spain. millan_jos@gva.es.
Papers in Europe PMC - 04Aller E7 papers · 2021
Grupo de Investigación en Enfermedades Neurosensoriales. Instituto de Investigación Sanitaria IIS-La Fe, Semisótano Escuela de Enfermería, Hospital Universitario La Fe, Avda. Campanar, 21, 46009, Valencia, Spain. elenaller@yahoo.es.
Papers in Europe PMC - 05Dinculescu A7 papers · 2025
Department of Ophthalmology, University of Florida, Gainesville, FL, 32610, USA.
Papers in Europe PMC - 06Jaijo T7 papers · 2021
Grupo de Investigación en Enfermedades Neurosensoriales. Instituto de Investigación Sanitaria IIS-La Fe, Semisótano Escuela de Enfermería, Hospital Universitario La Fe, Avda. Campanar, 21, 46009, Valencia, Spain. tjaijo@gmail.com.
Papers in Europe PMC - 07El-Amraoui A6 papers · 2026
Déficits Sensoriels Progressifs, Institut Pasteur, INSERM UMR-S 1120, Sorbonne Universités, Paris, France.
Papers in Europe PMC - 08Joensuu T6 papers · 2007
Department of Medical Genetics, University of Helsinki, Finland. sankila@helsinki.fi
Papers in Europe PMC - 09Kimberling WJ6 papers · 2012Papers in Europe PMC
- 10Liu X6 papers · 2024
Department of Ophthalmology, University of Pittsburgh, 3501 Fifth Avenue, Pittsburgh, PA, 15260, USA.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
2
interventional trials for this specific condition
2 interventional trials matched this specific condition name; 1 currently recruiting in our sample. 13 trials are registered for Usher syndrome, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026 · last trial check 28 July 2026
2 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 84.5th percentile).
medium confidence · 84.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
2 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06592131·NOT YET RECRUITING·BF844 Safety and Pharmacokinetic Study in Healthy Volunteers
Not reviewed·Conditions: Usher Syndrome Type 3·Matched via name phrase
Broader category: Usher syndrome
13
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07710196·NOT YET RECRUITING·A 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome
Not reviewed·Conditions: Retinitis Pigmentosa (RP) · Usher Syndrome·Matched via name phrase
- NCT06789445·RECRUITING·A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)
Not reviewed·Conditions: Primary Photoreceptor Disease · Retinitis Pigmentosa (RP) · Usher Syndrome · Inherited Retinal Disease (IRD)·Matched via name phrase
- NCT07290530·NOT YET RECRUITING·24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome
Not reviewed·Conditions: Retinitis Pigmentosa (RP) · Usher Syndrome·Matched via name phrase
- NCT06591793·RECRUITING·Study of Subretinally Injected AAVB-081 in Patients With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa
Not reviewed·Conditions: Usher Syndrome, Type 1B·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 2 · after dedupe 2 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 2 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (2)
- isrctn·ISRCTN11774433·No longer recruiting·PANACHE: A Pilot randomised trial comparing two forms of Absorbable versus Non-Absorbable sutures for Carpal tunnel Hand surgEry
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN65230311·No longer recruiting·Efficacy and safety of growth hormone treatment in short children born small for gestational age; effects of growth hormone levels on growth, insulin sensitivity and body composition
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Usher syndrome type 3 — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
("Usher syndrome type 3") OR ("CLRN1" OR "CLRN1 syndrome" OR "CLRN1-related" OR "HARS1" OR "HARS1 syndrome" OR "HARS1-related")ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Usher syndrome type 3"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 2 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"Usher syndrome"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: USH3
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T10:15:09.179Z
